- Shares in ZEN Graphene Solutions (ZEN) have jumped on results from the company’s growing portfolio of graphene-based products
- Preliminary cytotoxicity results of its antibiotic, antiviral, and antifungal compound demonstrated no apparent negative impacts on animals
- Polypropylene mask material treated with ZEN’s graphene-based ink was 98 per cent effective against COVID-19 after 108 days
- The company’s anti-COVID ink was also over 99 per cent effective against gram-positive and gram-negative bacteria
- ZEN Graphene Solutions is up 29.02 per cent and is currently trading for C$3.29 per share
Shares in ZEN Graphene Solutions (ZEN) have jumped on results from the company’s growing portfolio of graphene-based products.
Firstly, the company has completed preliminary cytotoxicity results of its antibiotic, antiviral, and antifungal graphene-based compound.
During phase one, animals were dosed with the compound, with one group receiving 1,000 milligrams per kilogram, and a second receiving 2,000 milligrams per kilogram. All animals at both dose levels demonstrated no negative impacts during the post-observation period.
This indicates that the compound could be a potential medical breakthrough for treatment of human-contracted pathogens.
The next stage of cytotoxicity testing will begin early next year, with repeat dose-testing completed by late January 2021. As such, ZEN Graphene expects to receive testing results from phase one in late January.
The company is also planning to start a new testing program at Mount Sinai Hospital, with Dr Tony Mazzulli. This program will focus on the efficacy of the biocidal compound on multi-drug resistant (MDR) organisms.
Secondly, ZEN Graphene’s graphene-based coating or ink is continuing to prove its worth in a world at the mercy of a pandemic. Polypropylene mask material treated with the coating was 98 per cent effective against the COVID-19 virus, even after 108 days.
Furthermore, the ink was over 99 per cent effective against gram-positive and gram-negative bacteria, at McMaster University.
ZEN Graphene’s CEO, Greg Fenton, said the company is continuing to make strides that could have far-reaching and extremely positive impacts on society.
“What started as a breakthrough in our fight against the current global pandemic has quickly evolved into a potential broad-spectrum solution for global infectious disease management,” he said.
“This is an area where society allocates a staggering amount of resources globally, and our solutions have the potential to play a key role,” he added.
ZEN Graphene Solutions is up 29.02 per cent and trading for C$3.29 per share, as of 10:50am EST.
